amisulpride / Generic mfg. - LARVOL DELTA

Formulation and Characterization of Amisulpride-Poly (Lactic-Co-Glycolic Acid) Nanoparticles Coated with Chitosan for Intranasal Delivery. (PubMed, AAPS PharmSciTech) - "Amisulpride chitosan-coated PLGA NPs demonstrated favourable physicochemical properties, solubility, stability, controlled drug release, and mucoadhesive profile with enhanced cell viability at specific concentrations across multiple epithelial cell lines compared with the drug solution and unloaded NPs. This work highlights the promising potential of Amisulpride Chitosan-coated PLGA NPs as an innovative intranasal nanocarrier for improved schizophrenia therapy."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Positive inotropic and chronotropic effects of amisulpride via stimulation of 5-HT4 serotonin receptors in the isolated atrium from mouse and humans. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "The positive inotropic effects of amisulpride in human right atrial preparations were reversed by 1 µM GR125487. These data indeed suggest that amisulpride acts as an agonist at the human cardiac serotonin receptor."

Journal • Preclinical • Cardiovascular

Symptom Network Dynamics during Antipsychotic Treatment in First-Episode Psychosis. (PubMed, Schizophr Bull) - "Temporal symptom dynamics, rather than static baseline relationships, differentiate response trajectories and could inform future research on early markers of non-remission. Absence of antipsychotic-specific effects suggests generic treatment mechanisms."

Clinical • Journal • CNS Disorders • Psychiatry

Temporal Mapping of Radiation-Induced Neural Injury and Mitigation in Human Cortical Organoids. (PubMed, bioRxiv) - "Two candidate radiation mitigators, NSPP and amisulpride, were tested for their therapeutic effects within the organoid system...Human cortical organoids recapitulate key features of radiation-induced neural injury, recovery, and therapeutic modulation, providing a robust, scalable, and human-relevant platform for studying CNS radiation biology and preclinical screening of candidate radiation mitigators. Human iPSC-derived cortical organoids enable study of human CNS radiation responses.Organoids recover after single-dose and fractionated radiation relevant to clinical exposure.The platform supports scalable, human-relevant testing of radiation mitigation strategies."

Journal • Brain Cancer • Oncology

Comparative efficacy and tolerability of antidopaminergic and muscarinic antipsychotics for acute schizophrenia: a network meta-analysis of randomised controlled trials indexed in international English and Chinese databases. (PubMed, Lancet) - "This network meta-analysis provides evidence for small-to-medium clinically relevant differences between antipsychotics in efficacy; this finding warrants stronger and more specific emphasis in clinical guidelines. Nonetheless, important differences in tolerability need to be considered for individualised drug choice, with partial dopamine agonists having overall better tolerability and xanomeline-trospium lacking adverse effects of dopamine-blocking agents but resulting in cholinergic and anticholinergic adverse events. Future research should directly compare xanomeline-trospium with other antipsychotics to confirm its efficacy; modern trials using clozapine early in schizophrenia are needed to establish whether it improves outcomes and prevents chronification."

Journal • Retrospective data • CNS Disorders • Psychiatry • Schizophrenia

Clozapine After 1 Failed Antipsychotic Drug Trial in First-Episode Psychosis: A Randomized Clinical Trial. (PubMed, JAMA Psychiatry) - P3 | "In phase 1, patients with FEP were randomized to receive oral olanzapine, risperidone, amisulpride, aripiprazole, or perphenazine for 8 weeks. This study provides some evidence for clinicians to consider regarding use of clozapine as the next sequential treatment after patients have failed an adequate trial with 1 of the more traditional antipsychotics. ClinicalTrials.gov Identifier: NCT03510325."

Clinical • Journal • CNS Disorders • Psychiatry • Schizophrenia • Schizophreniform Disorder

Clinical Practice Guideline on the Choice of First Antipsychotic Medicine for Females Experiencing a First-Episode of Psychosis. (PubMed, Schizophr Bull) - "This is the first CPG addressing antipsychotic choice for females with FEP. By prioritizing critically important patient outcomes and lived experience, the guideline supports safer, sex-sensitive prescribing for females that may improve treatment acceptability, adherence, and equity in psychosis care."

Clinical guideline • Journal • CNS Disorders • Psychiatry

Effect of Amisulpride Inclusion in a Postoperative Nausea and Vomiting Protocol: A Retrospective Pre-Post Analysis. (PubMed, Anesth Analg) - No abstract available

Journal • Retrospective data

Enhancing Recovery in Early Schizophrenia (clinicaltrials.gov) - P2 | N=180 | Not yet recruiting | Sponsor: Central Institute of Mental Health, Mannheim

New P2 trial • CNS Disorders • Psychiatry • Schizophrenia

Enhancing Recovery in Early Schizophrenia (clinicaltrials.gov) - P2 | N=180 | Recruiting | Sponsor: Central Institute of Mental Health, Mannheim | Not yet recruiting ➔ Recruiting | Initiation date: Nov 2016 ➔ Apr 2017

Enrollment open • Trial initiation date • CNS Disorders • Psychiatry • Schizophrenia

Enhancing Recovery in Early Schizophrenia (clinicaltrials.gov) - P2 | N=180 | Recruiting | Sponsor: Central Institute of Mental Health, Mannheim | Trial completion date: Dec 2025 ➔ Jun 2026 | Trial primary completion date: Dec 2024 ➔ Jun 2026

Trial completion date • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia

Enhancing Recovery in Early Schizophrenia (clinicaltrials.gov) - P2 | N=180 | Recruiting | Sponsor: Central Institute of Mental Health, Mannheim | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia

Enhancing Recovery in Early Schizophrenia (clinicaltrials.gov) - P2 | N=180 | Recruiting | Sponsor: Central Institute of Mental Health, Mannheim | Active, not recruiting ➔ Recruiting | Trial completion date: Mar 2023 ➔ Dec 2024 | Trial primary completion date: Mar 2023 ➔ Dec 2023

Enrollment open • Trial completion date • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia

Enhancing Recovery in Early Schizophrenia (clinicaltrials.gov) - P2 | N=180 | Active, not recruiting | Sponsor: Central Institute of Mental Health, Mannheim | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2021 ➔ Mar 2023 | Trial primary completion date: Jan 2021 ➔ Mar 2023

Enrollment closed • Trial completion date • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia

Enhancing Recovery in Early Schizophrenia (clinicaltrials.gov) - P2 | N=180 | Recruiting | Sponsor: Central Institute of Mental Health, Mannheim | Trial completion date: Mar 2020 ➔ Jan 2021 | Trial primary completion date: Mar 2020 ➔ Jan 2021

Trial completion date • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia

Regional absorption of talinolol mediated by intestinal transporters: insights from PBPK modeling analysis. (PubMed, Front Pharmacol) - "Plasma concentration-time profiles of several drugs, such as talinolol, bedaquiline, irbesartan, and amisulpride, exhibit dose-dependent dual or multiple absorption peaks, yet the mechanism underlying these phenomena remains elusive. Additionally, adjusting regional transporter activity-specifically lowering apical uptake and/or basolateral efflux transport in the lower jejunum and increasing them in the lower ileum-was key to describing the dual absorption peaks of talinolol. These findings indicate that regional differences in intestinal uptake and efflux influence the complex absorption profiles of talinolol and highlight the need for further investigation into additional transporter roles in basolateral transport in the enterocytes."

Journal

Linking Structural Features of Amisulpride and Sulpiride to Their Photoreactivity and Environmental Fate: The Role of NH2 Substitution in Photodegradation Behavior. (PubMed, Environ Sci Technol) - "Toxicity predictions showed that SUL photodegradation leads to detoxification, whereas AMI produces multiple transformation products with higher predicted toxicity. These findings demonstrate that -NH2 positional isomerism governs photoexcitation, indirect photoreactivity, and environmental risk."

Journal • CNS Disorders

Pharmacological rescue of social deficits in rats featuring Disrupted-in-Schizophrenia-1 (DISC1) protein aggregation. (PubMed, Schizophrenia (Heidelb)) - "Here, we tested whether continuous administration of atypical antipsychotics amisulpride or clozapine would rescue social deficits in tgDISC1 rats. Together, these findings demonstrate that amisulpride, a selective D2/D3 receptor antagonist, rescues social adaptability deficits linked to aberrant DISC1 signaling. The results also highlight the success of our precision psychiatry approach: the biological definition of a subset of schizophrenia by identifying DISC1 protein aggregates, the generation of a corresponding animal model and a successful pharmacotherapy of a clinically relevant phenotype."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

Enhancing Recovery in Early Schizophrenia (clinicaltrials.gov) - P2 | N=180 | Active, not recruiting | Sponsor: Central Institute of Mental Health, Mannheim | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2026 ➔ Dec 2027 | Trial primary completion date: Jun 2026 ➔ Dec 2027

Enrollment closed • Trial completion date • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia

Box-Behnken optimized salting-out assisted liquid-liquid extraction coupled with LC-MS/MS for sustainable amisulpride quantification in human plasma. (PubMed, J Chromatogr A) - "Following optimization, chromatographic separation was achieved using a C18 column with isocratic elution (acetonitrile:water with 0.1% formic acid, 70:30 v/v) and 4-minute analysis time, with multiple reaction monitoring employing transitions m/z370.1→242.1 for amisulpride and m/z376.2→165.1 for haloperidol internal standard. Clinical application in healthy volunteers (n = 5) following 200 mg oral amisulpride administration successfully characterized key pharmacokinetic parameters including Cmax (506 ng/mL), tmax (3.8 h), and t1/2 (13.3 h) over 48 h. Finally, multi-metric sustainability assessment using CaFRI (75/100), BAGI (77.5/100), and RGB12 (83.1/100 whiteness) frameworks confirmed achievement of white analytical chemistry through balanced analytical performance, environmental friendliness, and practical implementation feasibility. The method offers significant advantages including minimal waste generation, reduced solvent consumption, and enhanced throughput while..."

Journal

Rethinking Amisulpride: Could N-Methylation Result in a New and Even Better Antipsychotic? (PubMed, J Clin Psychiatry) - No abstract available

Journal • CNS Disorders

Levels of and changes in psychosis symptoms and clinical insight: Exploring the impact of differential antipsychotic mechanisms. (PubMed, Psychiatry Res) - "Symptom reduction is associated with improved insight, with early changes in positive symptoms exerting the fastest effect. Despite symptom improvement, aripiprazole PDA treatment was linked to less insight gain than DA treatment. These preliminary findings warrant further study."

Journal • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

Overall and Sex-Based Risk Factors for Hyperprolactinemia in Patients With Schizophrenia: A Retrospective Cohort Study. (PubMed, Curr Neuropharmacol) - "Multiple pharmacological and non-pharmacological factors contribute to HPRL in patients with schizophrenia, with notable sex-specific differences. The potential role of HPRL in breast cancer development among female patients requires further investigation."

Journal • Retrospective data • Breast Cancer • CNS Disorders • Oncology • Psychiatry • Schizophrenia • Solid Tumor

Exploring wanting and liking during positive human-animal interactions. (PubMed, Psychopharmacology (Berl)) - "These altered reward-related behaviours along with the absence of side-effects are the first indicators for the safe and effective use of amisulpride and naloxone to non-invasively study reward mechanisms in domesticated animals."

Journal

The value of repetitive transcranial magnetic stimulation combined with amisulpride enhancement olanzapine therapy for resistant treatment-refractory schizophrenia. (PubMed, Front Psychiatry) - "rTMS is a widely used treatment method for schizophrenia. This study found that rTMS combined with amisulpride enhanced olanzapine treatment for TRS can significantly improve patients' symptoms, cognitive function, and quality of life, with tolerability and safety."

Journal • CNS Disorders • Psychiatry • Schizophrenia